The molecular basis of myelodysplastic syndromes

Haematologica

Volumn 82, Issue 2, 1997, Pages 191-204

  Gallagher, Angela ^a   Darley, Richard L ^a   Padua, Roseann ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; CSF; Karyotypic anomalies; Molecular abnormalities; Myelodysplastic syndromes

Indexed keywords

ANTINEOPLASTIC AGENT; COLECALCIFEROL; CYTARABINE; DAUNORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 6; RETINOIC ACID; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; GENE MUTATION; HUMAN; INFECTION; KARYOTYPE; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS;

APOPTOSIS; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; DNA; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 0031438734     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (202)

1. Locatelli F, Zecca M, Pession A, Maseraci E, De Stefano P, Severi F. Myelodysplastic syndromes: the pediatric point of view. Haematologica 1995; 80:268-79.
2. McMullin MF, Chisholm M, Hows JM. Congenital myelodysplasia: a newly described disease entity? Br J Haematol 1991; 79:340-2.
3. Bennett JM. Classification of the myelodysplastic syndromes. Clin Hematol 1982; 15:909-23.
4. Mufti CJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59:425-33.
5. Worsley A, Oscier DG, Stevens J, et al. Prognostic features of chronic myelomonocytic leukemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 1988; 68:17-21.
6. Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7:1315-23.
7. Sanz CF, Sanz MA. Prognostic factors in myelodysplastic syndromes. Leuk Res 1992; 16:77-86.
8. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients Science 1990; 249:181-6.
9. Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations [published erratum appears in Cell 1990 Aug 10; 62(3):following 608]. Cell 1990; 62:193-201.
10. Ainsworth PJ, Rodenhiser DI, Costa MT. Identification and characterization of sporadic and inherited mutations in exon 31 of the neurofibromatosis (NF1)gene. Hum Genet 1993; 91:151-6.
11. Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 1991; 88:9658-62.
12. Li Y, Bollag G, Clark R, et al. Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 1992; 69:275-81.
13. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994; 330:597-601.
14. Blatt J, Jaffe R, Deutsch M, Adkins JC. Neurofibromatosis and childhood tumors. Cancer 1986; 57:1225-9.
15. Quesnel B, Preudhomme C, Vanrumbeke M, Vachee A, Lai JL, Fenaux P. Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplasic syndromes and acute myeloid leukemia. Leukemia 1994; 8:878-80.
16. Boultwood J, Fidler C, Lewis S, eta l. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q-chromosome in some patients with the 5q-syndrome. Blood 1993; 82:2611-6.
17. Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259:968-71.
18. Preudhomme C, Vachee A, Lepelley P, et al. Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. Br J Haematol 1994; 87:61.
19. Ahuja H. G, Jat PS, Foti A, Bar-Eli M, Cline MJ. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 1991; 78:3259-68.
20. Gilmore T, DeClue JE, Martin GS. Protein phosphorylation at tyrosine is induced by the v-erbB gene product in vivo and in vitro. Cell 1985; 40:609-18.
21. Hunter T. A tail of two src's: mutatis mutandis. Cell 1987; 49:1-4.
22. Marshall CJ. How does p21ras transform cells? Trends Genet 1991; 7:91-5.
23. Barbacid M. Ras genes. Ann Rev Biochem 1987; 56:779-827.
24. Bos JL Ras oncogenes in hematopoietic malignancies. Hemacol Pathol 1988; 2:55-63.
25. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R. Analysis of RA oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 1988; 85:9268-72.
26. Neri A, Murphy JP, Cro L et al. Ras oncogene mutation in multiple myeloma. J Exp Med 1989; 170:1715-25.
27. Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci USA 1988; 85:1629-33.
28. Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75:1684-90.
29. Lubbert M, Mirro J, Jr, Miller CW, et al. N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 1990; 75:1163-9.
30. Padua RA, Carter G, Hughes D, et al. RAS mutations in myelodysplasia detected by oligonucleotide hybridisation and transformation. Leukemia 1988; 2:503-10.
31. Yunis JJ, Boot AJ, Mayer MG, Bos JL. Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene 1989; 4:609-14.
32. Lyons J, Janssen JW, Bartram C, Layton M, Mufti GJ. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 1988; 71:1707-12.
33. Bar-Eli M, Ahuja H, Gonzalez-Cadavid N, Foti A, Cline MJ. Analysis of N- RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing. Blood 1989; 73:281-3.
34. Melani C, Haliassos A, Chomel JC, et al. Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease. Br J Haematol 1990; 74:408-13.
35. Bartram CR. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin N Am 1992; 6:557-70.
36. Vandenberghe E, Baens M, Stul M, et al. Alteration of N-ras mutation in a patient with AML M4 and trilineage myelodysplasia. Br J Haematol 1991; 79:338-40.
37. Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82:590-9.
38. Horiike S, Misawa S, Nakai H, et al. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 1994; 8:1331-6.
39. Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 1994; 8:638.
40. Lubbert M, Mirro J, Jr, Kitchingman G, et al. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene 1992; 7:263-8.
41. Cachia PG, Taylor C, Thompson PW, et al. Non-dysplastic myelodysplasia? Leukemia 1994; 8:677-81.
42. Taylor C, McGlynn H, Carter G, et al. RAS and FMS mutations following therapy for childhood acute lymphoblastic leukemia. Leukemia 1995; 9:466-70.
43. Carter G, Hughes DC, Clark RE, et al. RAS mutations in patients following cytotoxic therapy for lymphoma. Oncogene 1990; 5:411-6.
44. van Kamp H, de Pijper C, Verlaan-de Vries M, et al. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood 1992; 79:1266-70.
45. van Kamp H, Landegent JE, Jansen RP, Willemze R, Fibbe WE. Clonal hematopoiesis in patients with acquired aplastic anemia. Blood 1991; 78:3209-14.
46. Hirai H, Okada M, Mizoguchi H, et al. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood 1988; 71:256-8.
47. Tien HF, Wang CH, Chuang SM, et al. Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan. Cancer Genet Cytogenet 1994; 74:40-9.
48. Stephenson J, Lizhen H, Mufti GJ. Possible co-existence of RAS activation and monosomy 7 in the leukemic transformation of myelodysplastic syndromes. Leuk Res 1995; 19:741-8.
49. Jacobs A. Genetic abnormalities in myelodysplastic syndrome. Cancer Genet Cytogenet 1991; 56:1-6.
50. Taylor C, Hughes DC, Zappone E, et al. A screen for RAS mutations in individuals at risk of secondary leukemia due to occupational benzene exposure. Leuk Res 1995; 19:299-301.
51. Nakagawa T, Saitoh S, Imoto S, et al. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49:114-22.
52. Inokuchi K, Amuro N, Futaki M, et al. Transforming genes and chromosome aberrations in therapy-related leukemia and myelodysplastic syndrome. Ann Hematol 1991; 62:211-6.
53. Kurosawa M. [Molecular study on minute alterations of the p53 and the N-ras genes in hematologic malignancies]. Hokkaido Igaku Zasshi - Hokkaido J Med Sci 1994; 69:543-54.
54. Buhler-Leclerc M, Gratwohl A, Senn HP. Occurrence of point mutations in p53 gene is not increased in patients with acute myeloid leukemia carrying an activating N-ras mutation. Br J Haematol 1993; 84:443-50.
55. Sugimoto K, Hirano N, Toyoshima H, et al. Mutations of the p53 gene in myetodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993; 81:3022-6.
56. Kalmantis T, Kalmanti M, Vassilaki M, Spandidos DA. Analysis of immunohistochemical results of the ras oncogene product p21 in myelodysplastic syndromes. Anticancer Res 1993; 13:1103-6.
57. Gallagher A, Padua RA, Al-Sabah AI, Hoy T, Burnett AK, Darley RL. Aberrant expression of p21RAS but not p120GAP is a common feature of myelodysplasia. Leukemia 1995; 9:1833-40.
58. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA 1990; 87:1377-80.
59. Donner L, Fedele LA, Garon CF, Anderson SJ, Sherr CJ. McDonough feline sarcoma virus: characterization of the molecularly cloned provirus and its feline oncogene (v-fms). J Virol 1982; 41:489-500.
60. Wheeler EF, Rettenmier CW, Look AT, Sherr CJ. The v-fms oncogene induces factor independence and tumorigenicity in CSF-1 dependent macrophage cell line. Nature 1986; 324:377-80.
61. Wheeler EF, Askew D, May S, Ihle JN, Sherr CJ. The v-fms oncogene induces factor-independent growth and transformation of the interleukin-3-dependent myeloid cell line FDC-P1. Mol Cell Biol 1987; 7:1673-80.
62. Tobal K, Pagliuca A, Bhatt B, Bailey N, Layton DM, Mufti GJ. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 1990; 4:486-9.
63. Aurer I, Labar B, Nemet D, Ajdukovic R, Bogdanic V, Gale RP. FMS mutations in acute myeloid leukemia and myelodysplastic syndrome detected by DNA-sequencing and alle-specific restriction analysis (ASRA). Br J Haematol 1996; 93:136-7.
64. Baker AH, Cachia PG, Ridge S, et al. MS mutations in patients following cytotoxic therapy for lymphoma. Leuk Res 1995; 19:309-18.
65. Dibb NJ, Green SM, Ralph P. Expression of v-fms and c-fms in the hemopoietic cell line FDC-P1. Growth Factors 1990; 2:301-11.
66. Roussel MF, Downing JR, Rettenmeir CW, Sherr CJ. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell 1988; 55:979-88.
67. Roussel MF, Downing JR, Sherr CJ. Transforming activities of human CSF-1 receptors with different point mutations at codon 301 in their extracellular domains. Oncogene 1990; 5:25-30.
68. Bartram CR, Bohlke JV, Adolph S, Hameister H, Ganser A, Anger B, Heisterkamp N, Groffen J. Deletion of c-fms sequences in the 5q-syndrome. Leukemia 1987; 1:146-9.
69. Boultwood J, Rack K, Kelly S, et al. Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion. Proc Natl Acad Sci USA 1991; 88:6176-80.
70. Jaquet K, Kreipe H, Felgner J, Boultwood J, Parwaresch MR. Myelodysplastic disorders with hemizygous M-CSF receptor gene loss do not show point mutations of codon 969 within the remaining allele [letter]. Leukemia 1993; 7:650-2.
71. Morishita K, Parganas E, Willman C, et al. Activation of the EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400kb on chromosome 3q26. Proc Natl Acad Sci USA 1992; 89:3937-42.
72. Ohyashiki JH, Ohyashiki K, Shimamoto T, et al. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression. Blood 1995; 85:3713-8.
73. Dreyfus F, Bouscary D, Melle J, Ribrag V, Guesnu M, Varet B. Expression of the Evi-1 gene in myelodysplastic syndromes. Leukemia 1995; 9:203-5.
74. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8; 21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to drosophila segmentation gene, runt. Blood 1992; 80:1825-31.
75. Kwong YL, Chan V, Wong KF, Chan TK. Use of polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8; 21). Cancer 1995; 75:821-5.
76. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77:307-16.
77. Wlodarska I, Mecucci C, Marynen P, et al. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33; p13) translocation or its variant t(10;12)(q24; p13). Blood 1995; 85:2848-52.
78. Raynaud SD, Baens M, Grosgeorge J, et al. Fluorescence in situ hybridization analysis of t(3;12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood 1996; 88:682-9.
79. Young DC, Griffin JD: Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 1986; 68:1178-81.
80. Oster W, Lindemann A, Mertelsmann R, Herrmann F. Granulocyte-macrophage colony-stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF. Blood 1989; 73:64-7.
81. Oster W, Mertelsmann R, Herrmann F. Role of colony-stimulating factors in the biology of acute myelogenous leukemia. Int J Cell Cloning 1989; 7:13-29.
82. Oster W, Lindemann A, Mertelsmann R, Herrmann F. Production of macrophage-, granulocyte-, granulocyte-macrophage-and multicolony-stimulating factor by peripheral blood cells. Eur J Immunol 1989; 19:543-7.
83. Siitonen T, Savolainen ER, Koistinen P. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. Leukemia 1994; 8:631-7.
84. Bowen DT, Padua RA, Burnett AK, deCastro CM, Kaufman RE. Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots. Leukemia 1993; 7:1883-5.
85. Arland M, Fiedler W, Samalecos A, Hossfeld D. Absence of point mutations in a functionally important part of the extracellular domain of the c-kit proto-oncogene in a series of patients with acute myeloid leukemia (AML). Leukemia 1994; 8:498-501.
86. O'Bryan JP, Frye RA, Cogswell PC, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991; 11:5016-31.
87. Neubauer A, Fiebeler A, Graham DK, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 1994; 84:1931-41.
88. Sato K, Mano H, Ariyama T, Inazawa J, Yazaki Y, Hirai H. Molecular cloning and analysis of the human Tec protein-tyrosine kinase. Leukemia 1994; 8:1663-72.
89. Willman CL, Stewart CC, Longacre TL, et al. Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages. Blood 1991; 77:726-34.
90. Quintrell N, Lebo R, Varmus H, et al. Identification of a human gene (HCK) that encodes a protein-t tyrosine kinase and is expressed in hemopoietic cells. Mol Cell Biol 1987; 7:2267-75.
91. Lord KA, Abdollahi A, Thomas SM, et al. Leukemia inhibitory factor and interleukin-6 trigger the same immediate early response, including tyrosine phosphorylation, upon induction or myeloid leukemia differentiation. Mol Cell Biol 1991; 11:4371-9.
92. Zanke B, Squire J, Griesser H, et al. A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. Leukemia 1994; 8:236-44.
93. Cosman D, Lyman SD, Idzerda RL, et al. A new cytokine receptor superfamily. Trends Biochem Sci 1990; 15:265-270.
94. Miyajima A, Hara T, Kitamura T. Common subunits of cytokine receptors and the functional redundancy of cytokines. Trends Biochem Sci 1992; 17:378-82.
95. Renauld JC, Druez C, Kermouni A, et al. Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci USA 1992; 89:5690-4.
96. Vigon I, Dreyfus F, Melle J, et al. Expression of the c-mpl proto-oncogene in human hematologic malignancies. Blood 1993; 82:877-83.
97. Boultwood J, Lewis S, Wainscoat JS. The 5q- syndrome. Blood 1994; 84:3253-60.
98. Mitani K, Sato Y, Hayashi Y, et al. Two myelodysplastic syndrome cases with the inv(11)(p15q23) as a sole chromosomal abnormality. Br J Haematol 1992; 81:512-5.
99. Feder M, Finan J, Besa E, Nowell P. A 2p; 11q chromosome translocation in dysmyelopoietic preleukemia. Cancer Genet Cytogenet 1985; 15:143-50.
100. Berger R, Bloomfield CD, Sutherland GR. Report of the Committee on Chromosome Rearrangements in Neoplasia and on Fragile Sites. Cytogenet Cell Genet 1985; 40:490-7.
101. Baylin SB, Fearon ER, Vogelstein B, et al. Hypermethylation of the 5'-region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 1987; 70:412-7.
102. Malinen T, Palotie A, Pakkala S, Peltonen L, Ruutu T, Jansson SE. Acceleration of chronic myeloid leukemia correlates with calcitonen gene hypermethylation. Blood 1991; 77:2435-40.
103. Nelkin BD, Przepiorka D, Burke PJ, Thomas ED, Baylin SB. Abnormal methylation of the calcitonin gene marks progression of chronic myelogeneous leukemia. Blood 1991; 77:2431-4.
104. Ihalainen J, Pakkala S, Savolainen ER, Jansson SE, Palotie A. Hypermethylation of the calcitonin gene in the myelodysplastic syndromes. Leukemia 1993; 7:263-7.
105. Srivastava A, Boswell HS, Heerema NA, Nahrein P, Lauer RC, Antony AC. KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. Cancer Genet Cytogenet 1988; 35:61-71.
106. Knapp RH, DeWald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clinic Proc 1985; 6:507-16.
107. Roulston D, Espinosa R, Stoffel M, Bell GI, Le Beau MM. Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 1993; 82:3424-9.
108. Bristol A, Hall SM, Kriz RW, et al. Phospholipase C-148: chromosomal location and deletion mapping of functional domains. Cold Spring Harbor Symposia on Quantitative Biology 1988; 53(pt. 2): 915-20.
109. Kunze N, Yang GC, Jiang ZY, et al. Localization of the active type I DNA topoisomerase gene on human chromosome 20q11.2-13.1, and two pseudogenes on chromosomes 1q23- 24 and 22q11.2-13.1. Hum Genet 1989; 84:6-10.
110. Brown-Shimer S, Johnson KA, Lawrence JB, et al. Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B. Proc Natl Acad Sci USA 1990; 87:5148-52.
111. Heim S. Cytogenetic findings in primary and secondary MDS. Leuk Res 1992; 16:43-6.
112. Brynes RK, Swayne D, McCourty A, Dosik CM, Traweek ST, Slovak ML Detection of trisomy 8 by fluorescence in situ hybridization on bone marrow smears from patients with subtle myelodysplastic changes. Arch Pathol Lab Med 1994; 118:1196-200.
113. Kefalas P, Brown TR, Brickell PM. Signalling by the p60c-src family of protein-tyrosine kinases. Int J Biochem Cell Biol 1995; 27:551-63.
114. Zeidler R, Joos S, Delecluse HJ, et al. Breakpoints of Burkitt's lymphoma t(8;22) translocations map within a distance of 300 kb downstream of MYC. Genes Chromos Cancer 1994; 9:282-7.
115. Reed JC, Torigoe T, Turner BC, et al. Protooncogene-encoded protein kinases in interleukin-2 signal transduction. Semin Immunol 1993;5:327-36.
116. Siefff CA, Chessells JM, Harvey BAM, Pickthall J, Lawler SD. Monosomy 7 in childhood: a myeloproliferative disorder. Br J Haematol 1981; 49:235-49.
117. Fourth International Workshop on chromosomes in leukemia. Abnormalities of chromosome 7 resulting in monosomy 7 or in deletion of the long arm (7q-): review of translocations, breakpoints and associated abnormalities. Cancer Genet Cytogenet 1984; 11:300-3.
118. Kere J, Ruutu T, Lahtinen R, de la Chapelle A. Molecular characterisation of chromosome 7 long arm abnormalities in myefoid disorders. Blood 1987; 70:1349-53.
119. Ninth International workshop on human gene mapping. Human gene mapping. Cytogenet Cell Genet 1987; 46:1-762.
120. Fichelson S, Dreyfus F, Berger R, Melle J, Bastard L, Michlea J, Gisselbrecht S. Evi-1 expression in leukemia patients with rearrangements of the 3q25-q28 chromosomal region. Leukemia 1992; 6:93-9.
121. Russell M, List A, Greenberg P, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84:1243-8.
122. De Witte T. New treatment approaches for myelodysplastic syndrome and secondary leukemias. Ann Oncol 1994; 5:401-8.
123. Larson RA, Wernli M, Le Beau M, et al. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high dose cytaarabine. Blood 1988; 72:1333-9.
124. Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA. Multidrug resistence in hematopoietic cell lines, myelodysplastic syndromes and acute myelodysplastic leukemia. Br J Haematol 1989; 72:40-4.
125. Lepelley P, Soenen V, Preudhomme C, Lai JL, Cosson A, Fenaux P: Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 1994; 8:998-1004.
126. Griffin JD, Spriggs D, Wisch JS, Kufe DW. Treatment of preleukemia syndromes with continuous intraveneous infusion of low dose cytosine arabinoside. J Clin Oncol 1985; 3:982-91.
127. Clark RE, Ismail SA, Jacobs A, Payne H, Smith SA. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol 1987; 66:77-83.
128. Fabian I, Shvartzmayer S, Nagler A. In vitro growth and differentiation of marrow cells from myelodysplastic patients in the presence of a retinoidal benzoic acid deriviative. Leuk Res 1987; 11:635-40.
129. Takahashi T, Ichiba S, Okuno Y, et al. Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and proliferative disorders. Jap J Clin Hematol 1989; 30:1-10.
130. Wisch JS, Griffin JD, Kufe DW. Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 1983; 309:1599-602.
131. Koeffler HP, Heitgen D, Mertelsmann R, et al. Randomized study of 13-cis retinoic acid vs placebo in the myelodysplastic syndromes. Blood 1988; 71:703-8.
132. Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte macrophage colony stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317:1545-52.
133. Vadhan-Raj S, Broxmeyer HE, Hittelman WN. Use of granulocytemacrophage colony-stimulating factor in hematopoietic disorders: biology and nature of response. Semin Hematol 1992; 29:4-13.
134. Antin JH, Smith BR, Holmes W, Rosenthal DS. Phase I/II study of recombinant granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988; 72:705-13.
135. Jones TC. Recombinant human GM-CSF: present clinical results and potential use in oncologic and hematologic disorders. Bull Cancer 1991;78:1155-9.
136. Negrin RS, Haeber DH, Nagler A, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor. Blood 1992; 78:36-43.
137. Falk S, Seipelt G, Ganser A, et al. Bone marrow findings after treatment with recombinant human interleukin-3. Am J Clin Pathol 1991; 95:355-62.
138. Ganser A, Seipelt G, Lindemann A, et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990; 6:455-62.
139. Ganser A, Ottmann OG, Seipelt G, et al. Effects of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 1993; 7:696-701.
140. Nimer SD, Paquette RL, Ireland P, Resta D, Young D, Golde DW. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol 1994; 22:875-80.
141. Estrov Z, Kurzrock R, Talpaz M, Blake M, Gutterman JU. Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. Ann Hematol 1991; 63:297-301.
142. Greenberg P, Taylor K, Larson R, et al. Phase III randomized trial of G-CSF vs. observation for MDS. Blood 1993; 82 (suppl 1):196a.
143. Cazzola M, Ponchio L, Pedrotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996; 81:434-41.
144. Greenberg PL. In vitro marrow culture studies in the myelodysplastic syndromes. Semin Oncol 1992; 19:34-46.
145. Merchav S, Nielsen OJ, Rosenbaum H, et al. In vitro studies of erythropoietin dependent regulation of erythropoiesis in myelodysplastic syndromes. Leukemia 1990; 4:771-4.
146. Greenberg PL, Negrin R, Ginzton N. G-CSF synergises with erythropoietin for enhancing erythroid colony formation in myelodysplastic syndromes. Blood 1991; 78:38a.
147. Hellstrom-Lindberg E, Birgegard G, Carlsson M, et al. A combination of G-CSF and erythropoietin may synergistically improve the anemia in patients with MDS. Leuk Lymphoma 1993; 11:221-8.
148. Hellstrom-Lindberg E, Negrin R, Stein R. Prediction of responses to G-CSF and Epo treatmen of the anemia of myelodysplastic syndromes. Leuk Res 1994; 18 (suppl):53a.
149. Runde V, Aul C, Ebert A, Grabenhorst U, Schneider W. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. Eur J Haematol 1995; 54:39-45.
150. Glinsmann-Gibson B, Spier C, Baier M, Taetle R, Broudy VC, List AF. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplasric syndrome. Leukemia 1994; 8:827-32.
151. Ratajczak MZ, Luger SM, Gewirtz AM. The c-kit proto-oncogene in normal and malignant human hematopoiesis. Int J Cell Cloning 1992; 10:205-14.
152. Goselink HM, Williams DE, Fibbe WE, et al. Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells. Blood 1992; 80:750-7.
153. Zwierana H, Schollenberger S, Herold M, Schmalzl F, Besemer J. Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes. Leuk Res 1992; 16:1181-6.
154. Dong F, Byrnes RK, Tidow N, Welte K, Lowenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995; 333:487-93.
155. Janssen JW, Buschle M, Layton M, et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 1989; 73:248-54.
156. Weimar IS, Bourhis JH, de Gast GC, Gerritsen WR. Clonality in myelodysplastic syndromes. Leuk Lymphoma 1994; 13:215-221.
157. Vogelstein B, Fearon ER, Hamilton SR, et al. Clonal analysis using recombinant DNA probes from the X-chromosme. Cancer Res 1987; 47:4806-13.
158. Cachia PG, Culligan DJ, Thomas ED, Whittaker J, Jacobs A, Padua RA. Methylation of the DXS255 hypervariable locus 5' CCGG site may be affected by factors other than X-chromosome activation status. Genomics 1992; 14:70-4.
159. Tefferi A, Thibodeau SN, Solberg LA, Jr. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 1990; 75:1770-3.
160. Culligan DJ, Cachia P, Whittaker J, Jacobs A, Padua RA. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 1992; 81:346-52.
161. van Kamp H, Landegent JE, Jansen RP, Willemze R, Fibbe WE. Clonal hematopoiesis in patients with acquired aplastic anemia. Blood 1991; 78:3209-14.
162. Culligan DJ, Bowen DT, May A, White D, Padua RA, Burnett AK. Refractory anaemia with preleukemic polyclonal hemopoiesis and the emergence of monoclonal erythropoiesis on disease progression. Br J Haematol 1995; 89:675-7.
163. Asano H, Ohashi H, Ichihara M. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 1994; 84:588-94.
164. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-57.
165. Goldman AS, Baker MK, Piddington R, Herold R. Inhibition of programmed cell death in mouse embryonic palate in vitro by cortisol and phenytoin: receptor involvment and requirement of protein synthesis. Proc Soc Biol Med 1983; 174:239-43.
166. Lockshin RA and Zakeri Z. Programmed cell death and apoptosis. In: Tomei LD, Cope FO, eds. Apoptosis: the molecular basis of cell death. Current communication in cell and molecular biology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1991. vol. 3, p. 47-60.
167. Duke RC. Apoptosis in cell-mediated immunity. In: Tomei LD, Cope FO, eds. Apoptosis: The molecular basis of cell death. Current communication in cell and molecular biology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1991. vol. 3, p. 209-26.
168. Mc Conkey DJ, Orrenius X. Signalling in thymocyte apoptosis. In: Tomei LD, Cope FO, eds. Apoptosis: The molecular basis of cell death. Current communication in cell and molecular biology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1991. vol. 3, p. 227-46.
169. Raza A, Mundle S, Iftikhar A, et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 1995; 48:143-54.
170. Ohmori M, Ohori S, Ueda Y, Yoshida Y, Okuma M. Ineffective hemopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation of colony cluster formation. Int J Cell Cloning 1991; 9:521-30.
171. Clarke DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk Lymphoma 1990; 2:415-8.
172. Yoshida Y. Open forum. Hypothesis: apoptosis may be the mechanism responsible for premature intramedullary cell death in the myelodysplastic syndromes. Leukemia 1993; 7:144-6.
173. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 1991;352:345-7.
174. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849-59.
175. Boise LH, Gottschalk AR, Quintans J, Thompson CB. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Curr Top Microbiol Immunol 1995; 200:107-21.
176. Askew DS, Ashmun RA, Simmons BC, Cleveland JL Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6:1915-22.
177. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119-28.
178. Larson CJ. The BCL-2 gene, prototype of a gene family that controls programmed cell death (apoptosis). Ann Genet 1994; 37:121-34.
179. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609-19.
180. Sakai N, Ogiso Y, Fujita H, Watari H, Koike T, Kuzumaki N. Induction of apoptosis by a dominant negative H-ras mutant (116y)in kS62 cells. Exp Cell Res 1994; 215:131-6.
181. Arends MJ, McGregor AH, Toft NJ, Brown EJH, Wyllie AH. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br J Cancer 1993; 68:1127-33.
182. Wang HG, Miyashita T, Takayama S, et al. Apoptosis regulation by interaction of BCL-2 protein and RAF-1 kinase. Oncogene 1994; 9:2751-6.
183. Wang HG, Millan JA, Cox AD, et al. R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism. J Cell Biol 1995; 129:1103-14.
184. Hollstein M, Sidransky D, Vogelstein B, Harris CC.p53 mutations in human cancers. Science 1991; 253:49-53.
185. Fenaux P, Jonveaux P, Quiquandon I, et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991; 78:1652-7.
186. Lai JL, Preudhomme C, Zandecki M, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995; 9:370-81.
187. Jonveaux P, Fenaux P, Quiquandon I, et al. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 1991; 6:2243-7.
188. Tsushita K, Hotta T, Ichikawa A, Saito H. Mutation of p53 gene does not play a critical role in myelodysplastic syndrome and its transformation to acute leukemia [letter]. Br J Haematol 1992; 81:456-7.
189. Ludwig L, Schulz AS, Janssen JW, Grunewald K, Bartram CR. P53 mutations in myelodysplastic syndromes. Leukemia 1992; 6:1302-4.
190. Adamson DJA, Dawson AA, Bennett B, King DJK, Haites NE. P53 mutations in the myelodysplastic syndromes. Br J Haematol 1995; 89:61-6.
191. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistence to chemotherapy and short survival in hematological malignancies. Blood 1994; 84:3148-57.
192. Mori N, Wada M, YokotaJ, et al. Mutations of the p53 tumour suppressor gene in hematologic neoplasma. Br J Haematol 1992; 81:235-40.
193. Lepelley P, Soenen V, Preudhomme C, Merlat A, Cosson A, Fenaux P. bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia 1995; 9:726-30.
194. Campos L, Roualt JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81:3091-6.
195. Yuan J, Shaham S, Ledoux S, Ellis H, Horvitz H. The C elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1b converting enzyme. Cell 1993; 75:652.
196. Miura M, Zhu H, Rotello R, Hartwieg E, Yuan J. Induction of apoptosis in fibroblasts by IL-1b converting enzyme, a mammalian homologous of the C elegans cell death gene. Cell 1993; 75:653-60.
197. Anzai N, Kawabata H, Hirama T, et al. Marked apoptosis of human myelomonocytic leukemia cell line P39: significance of cellular differentiation. Leukemia 1994; 8:446-53.
198. MaherJ, Colona F, Baker D, Luzzatto L, Roberts I. Retroviral-mediated gene transfer of a mutant H-ras gene into normal human bone marrow alters myeloid cell proliferation and differentiation. Exp Hematol 1994; 22:8-12.
199. Darley RL, Baines P, Hoy TG, Burnett AK. Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ progenitor cells. Blood 1995;86:420a.
200. Satoh T, Nakafuku M, Miyajima A, Kaziro Y. Involvement of ras p21 protein in signat-transduction pathways from interleukin-2, interieukin-3, and granulocyte macrophage colony-stimulating factor, but not from interleukin-4. Proc Natl Acad Sci USA 1991; 88:3314-8.
201. Torti M, Marti KB, Altschuler D, Yamamoto K, Lapetina EG. Erythropoietin induces p21(ras) activation and pl20gap tyrosine phosphorylation in human erythroleukemia cells. J Biol Chem 1992; 267:8293-8.
202. Maruta H, Burgess AW. Regulation of the ras signaling network. Bioessays 1994; 16:489-96.